Skip to main content

Advertisement

Table 1 Patient characteristics (n = 7)

From: Long term disease-free survival and T cell and antibody responses in women with high-risk Her2+ breast cancer following vaccination against Her2

Patient Age Disease Stage Number + Lymph Nodes HER2 Status Prior Treatment/s Maintenance Hormones
Vaccinations: immature DC (GM-CSF, IL-4) + HER2 ICD protein control DC loaded with KLH and tetanus toxoid
#1 38 T3pN3 – IIIC > 10 > 80% cells overexpress by IHC AC-Taxol; trastuzumab Raloxifene (ER/PR+)
#2 56 T1cpN2M1 – IV 7 100% cells overexpress by IHC Taxol; HDC + Auto PBSCT DC-CEA vaccine Tamoxifen (ER/PR+)
#3 57 T3pN2 – IIIC 7 3+ doxorubicin HDC + Auto PBSCT None (ER/PR-)
Vaccinations: Mature DC (GM-CSF, IL-4, CD40-ligand, IFNγ) + HER2 ICD protein, E75 ECD peptide control DC loaded with KLH and CMV peptide
#4 47 T1pN2 – IIIA 8 3+ AC; Taxotere; Radiotherapy None (ER/PR-)
#5 58 T2pN3 – IIIC 11 2+ FAC; Taxol; XRT Tamoxifen (ER/PR+)
#6 38 IV (liver) 0 High Taxotere; Trastuzumab (prior to enrollment and then continued on maintenance > 4 years); FAC; Navelbine; RFA of liver lesion None (ER/PR-)
Vaccinations: DC (FLT3-ligand) + GM-CSF + CD40-ligand + IFNγ+ HER2 ICD protein control DC loaded with KLH, tetanus toxoid and CMV peptide
#7 45 T4N1 vs N0M0 – IIIB 0 @ surgery 3+ in 100% cells by IHC Neoadj AC; post-op Taxol; post-mastect RT None (ER/PR-)
  1. F = Fluorouracil, A = doxorubicin, cyclophosphamide; HDC + PBSC = high dose chemotherapy followed by peripheral blood stem cell transplant; RFA = radiofrequency ablation;
  2. IHC = immunohistochemistry
  3. Note: Different IHC methodologies were used by pathologists in characterizing HER2 expression during the time patients were enrolled in the study. FISH was not utilized.